Improving mRNA therapy for cancer treatment
Sequence optimization for mRNA cancer therapy
This study is working on improving cancer treatments by using mRNA technology to create therapies that are more effective and have fewer side effects, so patients can receive more personalized care tailored to their specific cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11063557 on NIH RePORTER |
What this research studies
This research focuses on enhancing mRNA technology to develop more effective cancer therapies, particularly through immunotherapy. It aims to create a systematic model that can optimize the sequences of mRNA to improve protein expression and therapeutic outcomes. By utilizing advanced algorithms and computational methods, the project seeks to identify the best mRNA sequences for targeting specific cancer cells, potentially leading to more personalized and effective treatments. Patients may benefit from therapies that are designed to be more effective and have fewer side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from advanced mRNA therapies.
Not a fit: Patients with non-cancerous conditions or those who do not respond to immunotherapy may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and targeted cancer therapies that improve patient outcomes.
How similar studies have performed: Previous research has shown promising results in optimizing mRNA therapies for other conditions, indicating potential success for this approach in cancer treatment.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Seelig, Georg — University of Washington
- Study coordinator: Seelig, Georg
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.